We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

The largest IPO in the U.S. stock market this year is born, with a 22% surge on its first day of trading.

The largest IPO in the U.S. stock market this year is born, with a 22% surge on its first day of trading.
Your browser does not support the video tag.

On the evening of May 4 Beijing time, Kenvue, a subsidiary of Johnson & Johnson, was listed on the New York Stock Exchange.

Kenvue's offering price was $22 per share, and its opening price was $25.53 per share. After opening, the stock price continued to rise, closing at $26.90, an increase of 22.27%; market capitalization exceeded $50.2 billion.

 7e39a1b44f71d1c7445ce2bf978a1adc_87514413609cc6fdd7250ebc86ff76c1.jpeg

Source: Screenshot from Baidu Stock Market

Calculated based on the offering price, Kenvue issued 172.8 million shares of common stock at an offering price of $22, raising a total of $3.8 billion.

This means that Kenvue is not only the largest US IPO since 2023, but also the largest US IPO since electric vehicle manufacturer Rivian went public in November 2021.

Kenvue is Johnson & Johnson's consumer health business company, resulting from a spin-off from the Johnson & Johnson Group. It began separating from Johnson & Johnson at the end of 2021. Its business covers three areas: self-care, skin health, and beauty, encompassing dozens of well-known Johnson & Johnson brands including Band-Aid, Neutrogena, Listerine, and Johnson's Baby Powder.

The Largest IPO in the US Stock Market in Nearly Two Years

Reportedly, Kenvue's actual offering size was increased from 151 million shares of common stock to 172.8 million shares, with an offering price of $22 per share, raising $3.8 billion, which will bring Kenvue's market capitalization to over $41 billion.

This may be the largest offering in the relatively quiet US IPO market this year, and also the largest US IPO since electric vehicle manufacturer Rivian went public in November 2021.

According to Dealogic data, as of the end of April this year, traditional US IPOs raised $2.3 billion in 2023. Kenvue's current fundraising amount far exceeds the total financing volume in the US stock market so far this year.

In fact, the US IPO market had already begun to cool down continuously in 2022.

Wind data shows that in 2022, 345 companies made their initial public offerings in the US market, raising only $4.812 million. The first-day break-issue rate was 28.7%, and the number of listed companies for the full year was only one-quarter of that in 2021, while the fundraising amount was just over 10% of that in 2021.

Among the companies listed in the US in 2022, the largest IPO project raised a total of only $1.68 billion, belonging to a financial company, Corebridge Financial.

Kenvue's listing may inject a shot of adrenaline into the "frozen" US IPO market over the past two years.

Johnson & Johnson Spins Off a $50 Billion Giant

Kenvue's predecessor was Johnson & Johnson's consumer health business division.

As early as November 2021, Johnson & Johnson announced it would separate its consumer health division from its pharmaceutical and medical device businesses.

In September 2022, Johnson & Johnson announced it would spin off its consumer health products division into an independent publicly traded company, naming the new company Kenvue.

In 2021, the overall revenue of the Johnson & Johnson Group was $93.8 billion, while the consumer health business accounted for $15.1 billion, less than one-sixth of the group's total revenue.

Regarding the newly formed Kenvue, Joseph Wolk, Chief Financial Officer of the Johnson & Johnson Group, stated that the newly established consumer goods company can provide sufficient cash flow for the group, helping to strengthen the strong investment-grade credit rating of the consumer goods business.

Notably, this division includes talcum powder products that have put Johnson & Johnson "under scrutiny."

Johnson & Johnson's Q1 2023 financial results showed that Q1 revenue increased by 5.6% year-on-year to $24.7 billion. However, due to "a special one-time charge," the company reported a net loss of $68 million, compared to a net profit of $5.149 billion in the same period last year.

The financial report indicates that the decline in company profits is related to litigation compensation for the talcum powder incidents. In April this year, Johnson & Johnson issued a statement announcing plans to pay $8.9 billion in compensation over the next 25 years to settle claims alleging that its baby powder and other talc-containing products cause cancer.

Although Johnson & Johnson has previously stated that the spin-off of the consumer health business is unrelated to the talcum powder lawsuits, it is undeniable that being deeply embroiled in talcum powder litigation still brings certain negative impacts to Johnson & Johnson's overall business development.

Spinning off Kenvue as an independently listed company may benefit the independent decision-making and healthy development of Johnson & Johnson's various business segments.

By the close of trading on that day, Kenvue rose 22.27%, closing at $26.90, with a market capitalization of $50.2 billion.

After completing the IPO, Johnson & Johnson will continue to hold 1.716 billion shares of Kenvue common stock, accounting for 91.9% of the total post-spin-off equity of 1.867 billion shares.

In fact, not only Johnson & Johnson, but multinational pharmaceutical companies such as Merck, Sanofi, and GlaxoSmithKline have also announced business spin-off plans in recent years.

In June 2021, Merck spun off women's health, biosimilars, and some mature drugs into a new company, Organon, and completed the separation. That same month, Organon listed on the NYSE, focusing on women's health.

In March 2022, Sanofi announced plans to spin off Euroapi, a subsidiary producing and selling active pharmaceutical ingredients, for listing on Euronext Paris in the first half of the year. After the spin-off, Sanofi will hold a 30% stake in Euroapi.

In July 2022, GlaxoSmithKline spun off its consumer healthcare business into Haleon, achieving dual listings on the London Stock Exchange and the New York Stock Exchange under the ticker code "HLN." Haleon owns numerous renowned consumer health brands, including toothpaste brand Sensodyne, vitamin brand Centrum, and calcium supplement brand Caltrate.

Behind these spin-offs, these multinational pharmaceutical companies are also facing multiple development challenges, such as significant pressure on profits, making spin-offs a "routine operation" for pharma companies to break through difficulties.

Boasting 44 Brands, Competing Head-to-Head with L'Oréal and P&G

Kenvue has 44 brands under its umbrella, including four mega-brands with revenues exceeding $1 billion and twenty brands with revenues over $150 million. Multiple brands rank first in North American or global niche markets, covering familiar names among Chinese consumers such as Tylenol, Neutrogena, Listerine, Johnson's Baby Powder, and Band-Aid.

In terms of positioning, Kenvue identifies L'Oréal and Procter & Gamble as competitors. The prospectus shows that the company's business is divided into three segments: Personal Health, Skin Health & Beauty, and Essential Health.

In 2022, Kenvue achieved net sales of $14.95 billion, slightly lower than $15.05 billion in 2021. Approximately half of the net sales in 2022 came from regions outside North America.

Among them, Kenvue's three major business segments contributed different revenue proportions:

The first segment is Personal Health, which accounted for 40.3% of revenue in 2022, with net sales of $6.03 billion. It includes over-the-counter medicines and wellness products, such as Tylenol for headache relief and cold symptom reduction, and Motrin pain relievers, totaling 16 brands.

The second segment is Skin Health & Beauty, which accounted for 29.1% of revenue in 2022, with net sales of $4.35 billion. This business primarily consists of skincare products, including 16 brands such as Neutrogena, Aveeno, Dr. Ci:Labo, and Dabao.

The third segment is Essential Health, which accounted for 30.6% of revenue in 2022, with net sales of $4.57 billion. It includes wound care, oral care, baby care, and women's health brands, comprising 12 brands such as Listerine, adhesive bandages, OB tampons, and infant care brand Vivvi & Bloom.

In the first quarter of 2023, Kenvue achieved net sales of $3.85 billion, a year-on-year increase of 7.3%.

Kenvue possesses a portfolio of renowned modern brands that have been established for over a century and earned the trust of generations of consumers. With Kenvue entering the capital markets, its product sales are highly likely to gain more reputation and profits.

Originally published on 金盒企业管理集团